Keyphrases
EphA2
100%
Ovarian Cancer
100%
Agonistic Antibody
100%
Antivascular Therapy
100%
Tumor
87%
Paclitaxel
75%
Confidence Interval
50%
Vascular Endothelial Growth Factor
37%
Combination Therapy
37%
Tumor Growth
25%
Immunoblotting
25%
CD31
25%
Endothelial Cell Apoptosis
25%
Phosphorylation
12%
Immunohistochemistry
12%
Protein Level
12%
MRNA Level
12%
Monoclonal Antibody
12%
Colocalization
12%
In Situ Hybridization
12%
Angiogenesis
12%
Immunofluorescence
12%
Cancer Model
12%
Immunohistochemical Analysis
12%
Statistical Test
12%
Ovarian Cancer Cells
12%
Basic Fibroblast Growth Factor (bFGF)
12%
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide
12%
Tumor Microenvironment
12%
Median Survival
12%
Taxanes
12%
Antiangiogenic
12%
Tyrosine Kinase Receptor
12%
Platinum Resistance
12%
Oncoprotein
12%
Agonistic
12%
Proliferating Cell nuclear Antigen
12%
End-labelling
12%
Vascular Density
12%
Antibody Constructs
12%
Antibody Treatment
12%
Biotin
12%
Mouse Ovarian Cancer Model
12%
Tumor Weight
12%
Terminal Deoxynucleotidyl Transferase
12%
P-27
12%
Deoxyribonucleoside Triphosphates
12%
Humanized Antibody
12%
Medicine and Dentistry
Tumor
100%
Ovarian Cancer
100%
Paclitaxel
85%
Combination Therapy
42%
Vasculotropin
42%
Endothelial Cell
28%
Programmed Cell Death
28%
Immunoblotting
28%
Tumor Progression
28%
Neoplasm
14%
Immunohistochemistry
14%
In Vitro
14%
Cancer
14%
Cancer Cell
14%
Angiogenesis
14%
Immunofluorescence
14%
Fibroblast Growth Factor 2
14%
Monoclonal Antibody
14%
Antiangiogenic Activity
14%
Tyrosine Kinase Receptor
14%
Tumor Microenvironment
14%
Oncoprotein
14%
MTT Assay
14%
Biotin
14%
TUNEL Assay
14%
DNA Nucleotidylexotransferase
14%
Proliferating Cell Nuclear Antigen
14%
Deoxyuridine
14%
Messenger RNA
14%
In Situ Hybridization
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Paclitaxel
100%
Combination Therapy
50%
Vasculotropin
50%
Tumor Growth
33%
Western Blot
33%
Neoplasm
16%
Mouse Model
16%
Fibroblast Growth Factor 2
16%
Monoclonal Antibody
16%
3 (4,5 Dimethyl 2 Thiazolyl) 2,5 Diphenyltetrazolium Bromide
16%
Antiangiogenic
16%
Tyrosine Kinase Receptor
16%
Oncoprotein
16%
Biotin
16%
Tumor Microenvironment
16%
Cycline
16%
DNA Nucleotidylexotransferase
16%
Deoxyuridine
16%
Messenger RNA
16%
Taxane
16%